• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates.

May 18, 2017 | Antiviral Research
Eugenia Z Ong et al.

Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates.

Eugenia Z Ong, Yadunanda Budigi, Hwee Cheng Tan, Luke N Robinson, Kirk J Rowley, Alexander Winnett, Sven Hobbie, Zachary Shriver, Gregory J Babcock, Eng Eong Ooi

>READ

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design